Cargando…
A retrospective observational study of early experiences of vedolizumab treatment for inflammatory bowel disease in the UK: The REVIVE study
Results from clinical trials show that vedolizumab is an efficacious treatment for inflammatory bowel disease, namely Crohn's disease (CD) and ulcerative colitis (UC). However, there is limited evidence from real-world clinical practice, especially on early clinical experiences in the UK. To de...
Autores principales: | Cummings, Fraser, Gaya, Daniel R., Levison, Scott, Subramanian, Sreedhar, Owen, Glynn, Rathmell, Anna, Glen, Fiona, Demuth, Dirk, Meadowcroft, Simon, Irving, Peter M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831399/ https://www.ncbi.nlm.nih.gov/pubmed/30817598 http://dx.doi.org/10.1097/MD.0000000000014681 |
Ejemplares similares
-
The ulcerative colitis endoscopic index of severity score is superior to reflecting long-term prognosis in ulcerative colitis patients treated with vedolizumab
por: Yan, Jing, et al.
Publicado: (2023) -
The safety of vedolizumab in a patient with Crohn’s disease who developed anti-TNF-alpha agent associated latent tuberculosis infection reactivation: A case report
por: Sugiyama, Yuya, et al.
Publicado: (2023) -
Association between bowel habits and quality of bowel preparation for colonoscopy
por: Lee, Dong-won, et al.
Publicado: (2017) -
Irritable Bowel Syndrome Increases the Risk of Epilepsy: A Population-Based Study
por: Chen, Chien-Hua, et al.
Publicado: (2015) -
Factors Associated With Small Bowel Obstruction Following Appendectomy: A Population-Based Study
por: Tseng, Chien-Jen, et al.
Publicado: (2016)